Form 4: Medicus Pharma Director Barry Fishman Receives New Stock Options and Accelerated Vesting

Medicus Pharma Ltd. Director Barry Fishman reported the grant of 25,000 new stock options and the accelerated vesting of 15,000 previously granted options.

Summary

• Barry Fishman, a Director and 10% Owner of Medicus Pharma Ltd. (MDCX), reported changes in his beneficial ownership of derivative securities.
• A new stock option to buy 25,000 Common Shares was granted on July 22, 2025, with an exercise price of $3.08 per share and an expiration date of July 22, 2030.
• This new option is scheduled to vest quarterly in four equal installments over one year.
• The Board of Directors approved accelerated vesting for 15,000 previously granted stock options on July 22, 2025.
• These 15,000 options, originally granted on December 17, 2024, with an exercise price of $2.75 (converted from CAD$3.95), were initially scheduled to vest quarterly over one year but are now fully vested.
• The conversion rate used for the existing option's exercise price was $1.00 USD to CAD$1.4379, reported by the Bank of Canada on December 30, 2024.
• Following these transactions, Barry Fishman directly beneficially owns 15,000 Common Shares via the first stock option and 25,000 Common Shares via the newly granted stock option.

Sentiment

Score: 7

Explanation: The filing indicates a director's increased equity stake and accelerated vesting, generally a positive sign of alignment between management and shareholder interests. However, it does not provide broader company performance metrics or financial results.

Positives

• A Director and 10% Owner received a new grant of 25,000 stock options, indicating continued equity alignment with the company's performance.
• The Board of Directors approved accelerated vesting for 15,000 previously unvested stock options, immediately increasing the director's vested equity stake.

Risks

• Potential dilution for existing shareholders if the stock options are exercised, increasing the number of outstanding shares.
• The value of the options is subject to the future market price of Medicus Pharma Ltd. common shares, which can be volatile.

Future Outlook

The newly granted 25,000 stock options are scheduled to vest quarterly in four equal installments over one year from the grant date of July 22, 2025.

Industry Context

This filing is a routine insider transaction report detailing equity compensation for a director. It does not provide information on broader industry trends or competitive landscape.

Comparison to Industry Standards

• Not applicable as this is an insider transaction report, not a performance or financial results filing. Comparisons to industry standards would typically involve financial metrics, operational efficiency, or strategic positioning, which are not detailed in a Form 4.

Corporate Governance

Related Party Transactions

• The grant of stock options and accelerated vesting for a director (Barry Fishman) constitutes a related party transaction as it involves compensation provided to a key management personnel.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also increased alignment of a director's interests with shareholder value through equity ownership.
• Management/Employees: The accelerated vesting and new option grant serve as incentives and compensation for the director.

Next Steps

• The new 25,000 stock options will vest quarterly over the next year, starting from July 22, 2025.

Key Dates

Keywords

Medicus Pharma, MDCX, Barry Fishman, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Grant, Vesting, Derivative Securities